Clinicopathological analysis of CD8‑positive lymphocytes in the tumor parenchyma and stroma of hepatocellular carcinoma

An,Jun‑Ling; Ji,Qiao‑Hong; An,Ji‑Jiang; Masuda,Shinji; Tsuneyama,Koichi

doi:10.3892/ol.2014.2516

Clinicopathological analysis of CD8‑positive lymphocytes in the tumor parenchyma and stroma of hepatocellular carcinoma

Authors:
- Jun‑Ling An
- Qiao‑Hong Ji
- Ji‑Jiang An
- Shinji Masuda
- Koichi Tsuneyama
View Affiliations

Affiliations: Department of Pathology and Pathophysiology, Medical College, Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, The Emergency Department, Songxian People's Hospital, Luoyang, Henan 471400, P.R. China, Department of Diagnostic Pathology, Koseiren Takaoka Hospital, Toyama 933‑0335, Japan, Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930‑0194, Japan
Published online on: September 9, 2014 https://doi.org/10.3892/ol.2014.2516
Pages: 2284-2290

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor‑infiltrating lymphocytes may be a manifestation of antitumor immunity. In the present study, hepatocellular carcinoma (HCC) and pericancerous non‑tumor liver tissues samples were obtained from 86 surgical patients who had not received preoperative treatment. The cellular expression levels of CD4 and CD8 were immunohistochemically examined in the two tissue groups using tissue microarrays, to evaluate their clinicopathological relevance. Immunohistochemically, CD4 and CD8 T cells were observed in the tumor parenchyma and tumor stroma, and the intensity of CD4 and CD8 immunoreactivity was homogeneous in all HCC samples examined. Morphometrically, the average numbers of CD4‑ and CD8‑positive T cells were significantly increased in the tumor stroma, compared with those in the tumor parenchyma (tumor stroma versus tumor parenchyma: 22±3.6 versus 7.4±0.9 in CD4, 32.8±4.2 versus 16±2.5 in CD8; both P<0.01). Furthermore, the average numbers of CD8‑positive T cells in the tumor parenchyma and stroma were significantly increased, compared with the average numbers of CD4‑positive cells (P<0.05). In addition, in the tumor parenchyma and stroma, the average numbers of CD8 T cells were significantly higher in patients with tumor diameters ≤5 cm compared with those in patients with tumor diameters >5 cm (diameter ≤5 cm versus diameter >5 cm: 18.1±3.3 versus 12.2±3.8 in tumor parenchyma, 36.5±4.8 versus 21.9±8.9 in tumor stroma; both P<0.05). In addition, CD8 expression was significantly enhanced in patients with chronic hepatitis and cirrhosis, compared with paired tumor parenchymal tissues (P<0.01). Furthermore, a significant positive correlation was observed between CD4 and CD8 expression in the tumor parenchyma and stroma (both P<0.001). These observations suggest that tumor parenchyma‑ or stroma‑infiltrating CD8 T cells may be involved in HCC tumor diameter control.

View Figures

View References

1	Schütte K, Bornschein J and Malfertheiner P: Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis. 27:80–92. 2009.
2	Kremsdorf D, Soussan P, Paterlini-Brechot P and Brechot C: Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 25:3823–3833. 2006.
3	Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P and Chisari FV: Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 188:341–350. 1998.
4	Fattovich G and Llovet JM: Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol. 44:1013–1016. 2006.
5	Naugler WE, Sakurai T, Kim S, et al: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317:121–124. 2007.
6	Parmiani G and Anichini A: T cell infiltration and prognosis in HCC patients. J Hepatol. 45:178–181. 2006.
7	Tobe T, Uchino J, Endo Y, Oto M, Okamoto E, Kojiro M, et al: Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer. 74:2772–2780. 1994.
8	Levy I and Sherman M: Liver Cancer Study Group of the University of Toronto: Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 50:881–885. 2002.
9	Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 357:539–545. 2001.
10	de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 6:24–37. 2006.
11	Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006.
12	Dieu-Nosjean MC, Antoine M, Danel C, et al: Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 26:4410–4417. 2008.
13	Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 14:518–527. 2008.
14	Chew V, Tow C, Teo M, et al: Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 52:370–379. 2010.
15	Wada Y, Nakashima O, Kutami R, Yamamoto O and Kojiro M: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 27:407–414. 1998.
16	Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 25:2586–2593. 2007.
17	Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003.
18	Kashef E and Roberts JP: Transplantation for hepatocellular carcinoma. Semin Oncol. 28:497–502. 2001.
19	Lu XY, Xi T, Lau WY, et al: Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol. 137:567–575. 2011.
20	Zhang B, Zhang Y, Bowerman NA, et al: Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68:1563–1571. 2008.
21	The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg. 19:98–129. 1989.
22	Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol. 22:696–699. 1995.
23	Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954.
24	Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998.
25	Hatta H, Tsuneyama K, Kumada T, et al: Freshly prepared immune complexes with intermittent microwave irradiation result in rapid and high-quality immunostaining. Pathol Res Pract. 202:439–445. 2006.
26	Kumada T, Tsuneyama K, Hatta H, Ishizawa S and Takano Y: Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol. 17:1141–1149. 2004.
27	Sato E, Olson SH, Ahn J, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:18538–18543. 2005.
28	Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature. 411:375–379. 2001.
29	Connolly JL, Schnitt SJ, Wang HH, Dvorak AM and Dvorak HF: Principles of cancer pathology. Holland-Frei Cancer Medicine. Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF and Frei E III: BC Decker, Inc.; Hamiton, ON, Canada: pp. 384–399. 2000
30	Zerbini A, Pilli M, Soliani P, et al: Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol. 40:102–109. 2004.
31	Spiotto MT and Schreiber H: Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 5:82005.
32	Singh S, Ross SR, Acena M, Rowley DA and Schreiber H: Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med. 175:139–146. 1992.
33	Blankenstein T: The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 17:180–186. 2005.
34	Kobayashi N, Hiraoka N, Yamagami W, et al: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 13:902–911. 2007.